B Cell Lymphoma Survival Rate and Life Expectancy: Revised International Prognostic Index

B cell lymphoma is not one disease but a few dozen heterogeneous diseases, or individual cancers, that affect the b-cells in the lymphatic system. However, the most common type of b cell lymphoma is diffuse large b-cell lymphoma (DLBCL), and researchers have come up with a rather handy method of determining prognosis for people with DLBCL ( Diffuse Large B Cell Lymphoma life expectancy). The method is known by its initials, the R-IPI, which stands for the Revised International Prognostic Index.

Call

The R-IPI works by identifying a specific patient group—those who have been diagnosed with DLBCL and who are then treated with the R-CHOP chemotherapeutic regimen.

The R-IPI asks five questions, and assigns a point per question when called for.

  1. Is the patient younger or older than 60? If younger, 0 points. If 60 or older, 1 point.
  2. What is the patient's ECOG performance status score? [see * below]. If 0-2, 0 points. If 3-4, 1 point.
  3. Is the patient's LDH normal or elevated? If normal, 0 points. If elevated, 1 point.
  4. How many extranodal sites are involved? If no more than 1, 0 points. If 2 or more, 1 point.
  5. What stage disease? If the patient's cancer is stage I or II, 0 points. If III or IV, 1 point.

B Cell Lymphoma Life Expectancy: The R-IPI then identifies three prognostic groups according to points.

  • 0 points: Prognosis, Very good (4-year progression-free survival 94%, overall survival, 94%)
  • 1-2 points: Prognosis, Good (4-year PFS 80%, OS 79%)
  • 3-5 points: Prognosis, Poor (4-year PFS 53%, OS 55%)

The R-IPI doesn't recognize risk groups with a perceived B cell lymphoma survival rate of under 50%.

Researchers are always looking for new methods to determine survival rates, especially among b cell lymphomas, because they are so common, but readers should be aware of the limitations of these indices since each person is different and each person's cancer is also different. It is also important to note that survival does not equal a cure.

*ECOG status: This is a scale to determine how a disease affects a patient's daily life. To see what each score means, refer to this explanation offered by the National Cancer Institute.

Source: Sehn LH et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood

Photo: Pexels

Call

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...